A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Discount pricing and poor first day defies the recent trend for floating device makers.
In terms of private investments, 2020 was the year of the liquid biopsy.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Welcome to the calm before the Covid-19 storm.